Background-Although women account for a significant proportion of heart failure (HF) hospitalizations, data on the quality of care and in-hospital outcomes in women are limited. Methods and Results-We examined The Joint Commission performance measures, other quality metrics, length of stay, and in-hospital mortality in women using 99 841 HF admissions (January 2005 to June 2009) at 248 hospitals participating in the American Heart Association Get With The Guidelines-Heart Failure registry. Women accounted for 50% of the HF admissions and were older (mean age, 74Ϯ14 versus 69Ϯ14 years), more likely to have hypertension (77% versus 72%), and less likely to have coronary disease (44% versus 53%) or renal insufficiency (18% versus 23%) than men (all PϽ0.001). The presenting symptoms were similar to men, but women had higher admission systolic blood pressure (mean, 144Ϯ31 versus 137Ϯ30 mm Hg; PϽ0.001) and ejection fraction (mean, 0.44Ϯ0.17% versus 0.34Ϯ0.16%; PϽ0.001). After adjustment for baseline differences, eligible women were less likely than men to have measurement of left ventricular function (adjusted odds ratio [OR], 0.81; 95% CI, 0.76 to 0.86) and to receive anticoagulation for atrial fibrillation (adjusted OR, 0.91; 95% CI, 0.86 to 0.96) or implantable cardioverter-defibrillators (adjusted OR, 0.70; 95% CI, 0.65 to 0.75) but were as likely to receive discharge instructions, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ␤-blockers, and smoking cessation counseling at discharge. Although the median length of stay was 4 days, women were more likely than men to be hospitalized Ͼ4 days (adjusted OR, 1.13; 95% CI, 1.10 to 1.16) and Ͼ7 days (adjusted OR, 1.07; 95% CI, 1.04 to 1.11). Women had comparable in-hospital mortality to men (adjusted OR, 1.05; 95% CI, 0.96 to 1.14). Conclusions-Compared to men, women hospitalized for HF differ in many clinical characteristics and length of stay but have similar clinical presentations, receive similar quality of care for most but not all measures, and experience similar in-hospital mortality. (Circ Heart Fail. 2011;4:589-598.)
initiated in 2005 by the American Heart Association. 10, 11 The GWTG-HF registry enrolls adults hospitalized with an episode of new or worsening HF as the primary reason for admission or with significant HF symptoms that develop during hospitalization in which HF was the primary discharge diagnosis. Participating institutions submit consecutive eligible patients to the GWTG-HF database in compliance with The Joint Commission and Centers for Medicare & Medicaid Services standards. Trained personnel abstract clinical data using standardized definitions; variables collected include demographic and clinical characteristics, medical history, previous treatments, contraindications to evidence-based therapies, and in-hospital outcomes. Hospitals use an interactive, Internet-based patient management tool (Outcome Sciences, Inc; Cambridge, MA) to submit clinical information regarding in-hospital care and outcomes. The Internet-based system performs checks to ensure that the reported data are complete. In addition, data quality is monitored for completeness and accuracy. Only sites and variables with a high degree of completeness are used in analyses. Participating institutions submit the GWTG protocol for review and approval by their Institutional Review Boards. The Duke Clinical Research Institute served as the data analysis center and has Institutional Review Board approval for analyzing the aggregate deidentified data for research purposes. Outcome Sciences, Inc, serves as the data collection and coordination center for GWTG.
Study Population
From January 2005 through June 2009, there were 102 708 admissions for HF to the 248 hospitals participating in GWTG-HF that collected detailed clinical data. Of these, we excluded 2867 admissions without information on sex, with the final analysis including 99 841 admissions at 247 hospitals (Figure 1 ).
Outcomes Measures and Definitions
Quality of care for hospitalized patients with HF was measured using prespecified quality measures of process of care. The primary quality measures in GWTG-HF are the 4 core measures of quality used by the Centers for Medicare & Medicaid and The Joint Commission 12 and include the following: (1) a complete set of written instructions at time of discharge addressing activity level, diet, discharge medications, follow-up appointment, weight monitoring, and instructions in case of worsening symptoms; (2) documentation of evaluation of left ventricular (LV) function (before or during hospitalization or planned for after hospitalization); (3) angiotensin -converting enzyme inhibitor (ACEI)/ angiotensin receptor blocker (ARB) prescription for LV systolic dysfunction (LVSD) in patients without documented contraindications or intolerance; and (4) adult smoking cessation counseling in patients with a history of smoking cigarettes. An additional GWTG-HF quality measure, ␤-blocker use at discharge for patients with HF and LVSD without documented ␤-blocker contraindications or intolerance, also was assessed. A composite quality measure (proportion of successes among the quality measures relevant for an individual patient) was used. An additional summary measure for 100% compliance (defect-free measure) with all 5 primary quality measures was used. Additional quality measures were assessed, including (1) anticoagulant at discharge for patients with atrial fibrillation, (2) evidence-based ␤-blocker (bisoprolol fumarate, carvedilol, metoprolol succinate) prescribed at discharge for patients with LVSD, (3) aldosterone antagonists prescribed at discharge for LVSD, (4) black patients with LVSD prescribed hydralazine/isosorbide dinitrate at discharge, and (5) patients with an LV ejection fraction (LVEF) Յ35% and without contraindications who had an implantable cardioverter-defibrillator (ICD) placed before or during hospitalization or had a referral for an ICD at discharge. Length of stay was calculated as the number of days from admission to discharge. The mortality end point included all in-hospital deaths, and the cause of death was assigned based on chart review.
Statistical Analysis
Continuous variables are reported as meanϮSD for normally distributed variables and median (interquartile range) for nonnormally distributed variables. Categorical variables are reported as percentages. Statistical significance was assessed with 2 test for categorical variables and Wilcoxon rank sum test for continuous variables. The relationship of sex with baseline and clinical characteristics, inhospital procedures, discharge status, in-hospital mortality, and compliance with quality-of-care measures was explored using contingency tables. To further examine these associations with sex, multivariable logistic regression using generalized estimating equations to account for hospital clustering was performed to compute odds ratios (ORs) and 95% CIs of the implementation of the prespecified quality measures, in-hospital mortality, and length of stay above the median and Ͼ7 days.
Multivariable modeling included the following patient and hospital variables that may affect quality of care and prognosis in hospitalized patients with HF: age, body mass index, heart rate, systolic blood pressure, LVEF, and number of beds as continuous variables; race and hospital region as categorical variables; and medical history (chronic obstructive pulmonary disease, diabetes, prior HF, hypertension, dyslipidemia, prior myocardial infarction, peripheral vascular disease, renal insufficiency, and stroke) and academic status as dichotomous variables. For the in-hospital mortality, we used a previously validated mortality model, 13 which included serum sodium and blood urea nitrogen (as continuous variables) because these have been shown to be important predictors of in-hospital outcomes. 14, 15 A multiple imputation procedure was used in the case of missing variables. PՅ0.05 was considered significant for all tests. All analyses were performed using SAS version 9.1 software (SAS Institute Inc; Cary, NC).
Results
Women (nϭ49 225) accounted for approximately one half of the 99 841 admissions; over time, there was a slight decrease in the percentage of women admitted with HF (50.5% in 2005 to 48.1% in 2009, PϽ0.001 for trend). Table 1 shows the baseline characteristics of patients enrolled in the GWTG-HF registry. 
Klein et al Outcomes in Women Hospitalized for Heart Failure
Women tended to be older than men (mean age, 74Ϯ14 versus 69Ϯ14 years; PϽ0.001); have a lower prevalence of coronary artery disease (44% versus 53%, PϽ0.001), peripheral vascular disease (10% versus 13%, PϽ0.001), and renal insufficiency (18% versus 23%, PϽ0.001); but have a higher prevalence of hypertension (77% versus 72%, PϽ0.001) and anemia (20% versus 15%, PϽ0.001). On presentation to the hospital, close to two thirds of patients had dyspnea on exertion, and 30% had orthopnea or paroxysmal nocturnal dyspnea, but only one half had signs of volume overload (elevated jugular venous pressure, pulmonary rales, or lower-extremity edema). Although women in general had similar symptoms and physical findings on admission, they had higher admission blood pressures than men (mean systolic blood pressure, 144Ϯ31 versus 137Ϯ30 mm Hg; PϽ0.001). As expected, women had higher LVEF than men (mean, 0.44Ϯ17 versus 0.34Ϯ16; PϽ0.001), and more women had HF with preserved LVEF (Ͼ0.40) (56% versus 32%, PϽ0.001). In general, there were minor differences in the admission medications between women and men ( Table 1) . Although less than one fourth of patients admitted with HF had procedures performed during their hospital stay, women were significantly less likely to undergo any procedure than men (18% versus 25%, PϽ0.001) ( Table 2 ). One half of the patients had a history of coronary artery disease, and 19% of admissions were associated with chest pain. Less than 9% of the patients underwent ischemic evaluation either noninvasively or with coronary angiography, and percutaneous or surgical revascularization was performed in Ͻ2% of the patients ( Table 2) .
On average, patients lost 2.4 kg (2.36% of admission weight) between admission and discharge, with women losing significantly less weight than men (mean, 1.9 kg [2.03% of admission weight] versus 2.8 kg [2.66% of admission weight]; PϽ0.001) ( Table 2) . Although 90% of patients improved symptomatically, only one half were completely asymptomatic by the time of discharge, with minor differences between women and men. The majority of patients were discharged to home, but significantly more women were discharged to assisted living or skilled nursing facilities than men (23% versus 14%, PϽ0.001) ( Table 2) . Table 3 shows the main performance measures for HF quality of care. Provision of discharge instructions; smoking cessation counseling; and use of an ACEI/ARB, ␤-blockers, and aldosterone antagonists in patients with LVSD were similar between men and women. Only one fourth of eligible black men and women with LVSD received hydralazine/isosorbide dinitrates at hospital discharge. In multivariate analysis, women had 20% lower odds of receiving this therapy despite higher admission blood pressures than men. After adjustment for patient and hospital characteristics and the correlation of data within hospitals, provision of discharge instructions; smoking cessation counseling; and use of ACEI/ARB, ␤-blockers, and aldosterone antagonists in patients with LVSD were similar between men and women (Table 4 ). After adjustment, women had 20% lower odds of receiving an LV function assessment, 10% lower odds of receiving anticoagulation therapy for atrial fibrillation, and 40% lower odds of receiving an ICD compared with men. When trends in the performance measures were examined over time, we observed a continuous improvement for most measures, with the greatest magnitude of improvement occurring after the first year in the program (Figure 2 ). The overall observed sex differences in performance measures also were maintained over time.
Because prior literature suggests that minorities and elderly persons may have lower rates of uptake of evidence-based therapies and implementation of quality metrics, we performed sex/race and sex/age interactions for all the performance measures. In sex/race interactions, we found that use of ACEI/ARB was significantly higher in white women (Pϭ0.004 for the interaction). White women also were more likely to comply with the defect-free measure (Pϭ0.015 for the interaction). In sex/age interactions (using a median age of 74 years as the cutoff), we observed that older women were more likely to conform to the composite quality measure (PϽ0.001 for the interaction) and to the defect-free measure (Pϭ0.015 for the interaction). No other sex/race and sex/age interactions were significant.
The median length of stay was 4 days (interquartile range, 3 to 7 days) in women and 4 days (interquartile range, 2 to 7 days) in men (PϽ0.001). On univariate analysis, women were more likely to be hospitalized Ͼ4 days and Ͼ7 days than men. After adjustment for baseline characteristics, medical history, systolic blood pressure, heart rate, LVEF, and hospital characteristics, female sex was still associated with hospital stays Ͼ4 days (adjusted OR, 1.13; 95% CI, 1.10 to 1.16) or Ͼ7 days (adjusted OR, 1.07; 95% CI, 1.04 to 1.11). When patients with preserved and depressed LVEF were examined separately, results were similar (data not shown).
There were 2914 in-hospital deaths (1472 women) reported among the 99 841 patients in the study cohort (2.99%). After adjustment for baseline characteristics, medical history, systolic blood pressure, heart rate, LVEF, blood urea nitrogen, serum sodium, and hospital characteristics, women had a comparable in-hospital mortality to men (adjusted OR, 1.05; 95% CI, 0.96 to 1.14; Pϭ0.29). These results were similar when patients with preserved and depressed LVEF were examined separately. In addition, age-stratified analyses yielded no age/sex interaction (data not shown).
Discussion
Epidemiological and clinical studies have suggested sex-related differences in the incidence and prognosis of outpatients with HF, 7,16 -19 as well as in the delivery of guideline-recommend HF treatments. 3, 5, 20, 21 The present analysis conducted in a large observational registry extends these findings in patients hospitalized for HF. The main findings of our study are the following: (1) Women comprise one half of the patients admitted to the hospital with HF and have different comorbidities and clinical profiles but similar presenting symptoms compared to men; (2) provision of most performance measures for HF quality of care is similar between hospitalized men and women, with very few sex/race and sex/age interactions; (3) ICD implantation in patients with LVEF Յ35% occurs in a minority of indicated patients (40%) and in a considerably lower proportion of women compared to men (32% versus 45%); (4) anticoagulation for atrial fibrillation is underused (60%) and occurs in significantly fewer women than men; and (5) women hospitalized for HF have an increased length of stay, are less likely to undergo procedures, and have a less effective diuresis than men, despite a similar clinical profile.
Despite women being at high risk of morbidity and mortality from HF, previous studies have shown that they are less likely to be treated with guideline-recommended HF therapies than men. 3, 5, 21 In the present analysis of the quality of care provided by hospitals enrolled in the GWTG-HF program, provision of discharge instructions and smoking cessation counseling and use of ACEI/ARB and ␤-blockers in patients with LVSD were high (Ն90%) and similar between men and women. More white than minority women were prescribed ACEI/ARB perhaps because of a lingering belief that renin-angiotensin-aldosterone system antagonists may be less effective in black patients. Recent clinical trials, however, have not confirmed this hypothesis, and although some differences in response to drug treatments may exist, racebased therapy should be approached with caution, if at all. 22 Female patients with HF had better than previously observed quality-of-care measures and treatment with guidelinerecommended HF therapies. In the Acute Decompensated Heart Failure National Registry (ADHERE), discharge instructions and smoking cessation counseling were provided to only one third of the patients, with women faring worse than men. 19 These quality metrics have improved in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF), where close to 60% of patients received them. 23 The use of ACEI/ARB and ␤-blockers for patients with LVSD has equally improved from 50% to 55% of patients receiving them in the ADHERE to close to 85% of patients receiving them in the OPTIMIZE-HF registry. As in the case of discharge instructions and smoking cessation counseling, the sex gap in the use of life-saving pharmacotherapy narrowed significantly. 18, 20 In the outpatient cardiology practice setting, the IMPROVE-HF (Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) registry showed that in both sexes, 80% of outpatients with LVSD were receiving ACEI/ARB, and 85% were treated with ␤-blockers. 24 The improvement seen in these quality metrics and recommended pharmacotherapy among ADHERE, OPTIMIZE-HF, IMPROVE-HF, and the present study, along with elimination of the sex gap, may reflect an increasing awareness of the treating physicians as well as efforts made over time by healthcare facilities to comply with national guidelines and mandated quality-of-care metrics. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Although the ADHERE and OPTIMIZE-HF registries enrolled patients between 2001 and 2004, the present study examined patients hospitalized with HF between 2005 and 2009. During this time period, several iterations of HF guidelines have been published that emphasized the benefits of these therapies and provided solutions for increasing their uptake in patients with LVSD. 25, [27] [28] [29] Although the present study did not include postdischarge information, use of ACEI/ARB and ␤-blockers in patients with LVSD has been associated with lower postdischarge mortality and readmission 12 ; thus, the present findings of high uptake and lack of sex differences in their use will likely translate into improved outcomes in both women and men.
Favorable results in the prior quality metrics were in sharp contrast with a significant underuse and large sex discrepancy in placement of an ICD for primary prevention in patients with LVSD. Despite being a class I recommendation for patients with LVEF Յ35%, 25, 29 we found that ICD implantation or planned placement after hospital discharge occurred in only 40% of eligible patients, with women being 40% less likely to receive an ICD than men. Women were 20% less likely than men to undergo measurement of LVEF, but this difference probably was not sufficient to explain the variation in ICD implantation because 95% of patients had assessment of LV function.
Although the total number of eligible patients receiving an ICD increased from the ADHERE registry to OPTIMIZE-HF (10% to 40%), it showed no further improvement in the GWTG-HF in contrast with the improvements seen in the use of evidencebased pharmacotherapy. 19, 23 In addition, the sex disparities in the use of ICD persisted over time (with an absolute difference of about 10% in women compared to men), again in contrast with the improvements seen in other performance measures. 19, 23 Over the past 2 decades, survival in women with HF has improved to a lesser degree than in men, and the underuse of evidence-based therapies may be one of the reasons. 8, 30 Less than 30% of participants in the major ICD trials for primary prevention of sudden death in HF were women, and these trials were underpowered to adequately assess the efficacy of ICD specifically in subgroups of women. [31] [32] [33] However, these trials have not shown major interactions based on sex for efficacy; therefore, until there is significant contrary evidence, professional society guidelines suggest that women with HF and LVEF Յ35% should be offered ICD therapy for primary prevention of sudden death. 24, 29 We also found in the present study that anticoagulation for atrial fibrillation is underused (60% of eligible patients) and occurs in significantly fewer women than men (59% versus 64%). A prior analysis of GWTG-HF data showed that the mean CHADS2 (congestive HF, hypertension, age Ն75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score in this cohort was 3, translating into a risk of stroke of Ϸ6% per year. 34 Considering that women with atrial fibrillation, particularly those aged Ͼ75 years, are more prone to stroke than men, 35, 36 the decreased use of warfarin in women with HF is cause for great concern. The reason for the observed sex difference may be related to the general belief that women are more vulnerable than men to warfarin-associated hemorrhage, leading to reluctance among physicians to prescribe anticoagu- lation in women with atrial fibrillation. However, 2 large studies demonstrated that maintaining the international normalized ratio within the therapeutic range was associated with similar rates of major bleeding in women and men. 35, 36 Because warfarin reduces the risk of stroke by 60% and death by 25% compared with no antithrombotic treatment equally in men and women with atrial fibrillation, 37 further efforts should be undertaken to improve anticoagulation in all patients with HF and atrial fibrillation.
We found in the present study that hospitalized women with HF appear to have an increased length of stay, are less likely to undergo procedures, and have a less effective diuresis than men, and women are more likely to be discharged to assisted living or skilled nursing facilities than men. These findings occurred despite the fact that women had a fairly similar clinical profile as men and mirror those from the OPTIMIZE-HF program. 23 It is possible that despite a similar clinical profile, women have a higher functional impairment related to their overall older age, explaining the longer length of stay and the higher number of women discharged to intermediate-term-care facilities. The increased frailty compared to men could be perceived by treating physicians as a relative contraindication to recommending ICD implantation for women with HF and LVEF Յ35%, thus explaining the large variation of ICD use between the sexes. Future studies aimed at exploring functional capacity (either using the Kansas City Cardiomyopathy Questionnaire or 6-minute walk test) should provide further insights into these issues. 38 In-hospital mortality was low (3%). After adjustment for baseline and other important characteristics, it was similar between men and women.
The present study had several limitations. First, data from this voluntary, hospital-based, quality improvement program were collected by medical chart review and, therefore, depend on the accuracy and completeness of the documentation and abstraction. Second, the GWTG-HF program may include hospitals with a higher likelihood of following evidence-based recommendations, and the rates of achieving compliance with quality measures may exceed those in overall community practice. In addition, participation in the GWTG-HF registry is voluntary and thus may select for hospitals with certain characteristics, thereby resulting in selection bias. However, patient characteristics and outcomes for hospitals in the precursor program to GWTG-HF were similar to the nation as a whole for fee-forservice Medicare patients. 39 Third, unmeasured confounders may have influenced the treatment rates and clinical outcomes. Fourth, because of data collection limitations, potential differences in intravenous therapies during hospitalization were not accounted for and may explain some of these findings. Finally, because we did not have access to outpatient follow-up information, we were unable to determine the effects of the reported sex differences in quality metrics on postdischarge outcomes.
Conclusions
Women hospitalized with HF have different clinical characteristics but similar clinical presentations and in-hospital mortality compared to men. Women receive comparable quality of care for most, but not all measures; specifically, women were less likely to undergo evaluation of LV function and receive anticoagulation for atrial fibrillation or ICD for LVSD with an LVEF Յ35%. Finally, hospitalized women with HF experience an increased length of stay compared to men. Further research is needed to understand the reasons for these differences at the patient, physician, and hospital levels.
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